Mixing Systems: How to Stay One Step Ahead Of Biopharma Supply Chain Constraints

Supply chain disruptions are not a new concern for the world of biotech and biopharma. As the industry pushes to develop therapeutics faster and more efficiently, the need for bioprocess raw materials is mounting – and there are simply not enough. While much focus has been placed on active pharmaceutical ingredients (APIs) used for small molecule drugs, another real problem is the implications for companies producing biologic therapies and ensuring they have the right bioprocess materials.

Here we will examine single-use supply constraints that interfere with bioprocess operations and have been exacerbated by the COVID-19 pandemic and highlight Entegris solutions that can help minimize production delays.